[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
November 3, 1999

Continuing Shortage of IGIV

Author Affiliations

Not Available

Not Available

JAMA. 1999;282(17):1613. doi:10.1001/jama.282.17.1613

There is a continuing, serious shortage of immune globulin intravenous (IGIV), a plasma-derived product approved for the treatment of primary immunodeficiency, immune-mediated thrombocytopenia (ITP), Kawasaki disease, bone marrow transplantation, chronic B-cell lymphocytic leukemia, and human immunodeficiency virus type 1 (HIV-1) in pediatric patients.

The amount of IGIV distributed in the first 7 months of 1999 (8919 kg) was about 10% below the amount distributed in 1996 and nearly the same as in the first 7 months of 1998 (8746 kg). The consequences of this shortage were indicated in a March 1998 survey by the Immune Deficiency Foundation, which found that 86% of physicians treating immunodeficient patients with IGIV had difficulty obtaining the product (MMWR Morb Mortal Wkly Rep. 1999;48:159-162). A more recent survey by IDF has found only a slight improvement in this situation.

First Page Preview View Large
First page PDF preview
First page PDF preview